We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 148.53 | 0 | 01:00:00 |
From Apr 2019 to Apr 2024
By Colin Kellaher
Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of Tremfya for the treatment of adults with active psoriatic arthritis.
The drug maker said it expects a final decision from the European Commission, which generally follows the CHMP's advice, later this year.
Tremfya is currently approved in the EU for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 16, 2020 08:21 ET (12:21 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
